Teleflex (NYSE:TFX) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Teleflex (NYSE:TFX) from a hold rating to a sell rating in a research report report published on Saturday morning.

A number of other equities analysts have also recently issued reports on TFX. Needham & Company LLC increased their target price on Teleflex from $147.00 to $159.00 and gave the stock a “buy” rating in a report on Friday. BMO Capital Markets started coverage on Teleflex in a report on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price target on the stock. Royal Bank Of Canada raised Teleflex from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $135.00 to $155.00 in a research report on Friday, May 8th. Mizuho increased their price objective on Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Finally, Piper Sandler raised Teleflex from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $140.00 to $160.00 in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $148.90.

Teleflex Stock Up 2.3%

Teleflex stock opened at $139.86 on Friday. The stock has a market capitalization of $6.19 billion, a PE ratio of -6.13, a price-to-earnings-growth ratio of 1.02 and a beta of 0.81. Teleflex has a twelve month low of $100.18 and a twelve month high of $144.19. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. The company has a 50 day moving average of $131.11 and a 200-day moving average of $121.71.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm’s revenue was up 32.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities research analysts anticipate that Teleflex will post 6.7 EPS for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Monday, May 25th were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 1.0%. The ex-dividend date was Friday, May 22nd. Teleflex’s payout ratio is presently -5.96%.

Hedge Funds Weigh In On Teleflex

A number of large investors have recently modified their holdings of the business. Banque Cantonale Vaudoise increased its position in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 113 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Teleflex during the fourth quarter valued at approximately $37,000. UMB Bank n.a. boosted its position in Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 113 shares during the last quarter. Sound Income Strategies LLC bought a new position in Teleflex in the fourth quarter valued at approximately $45,000. Finally, Kestra Advisory Services LLC bought a new position in Teleflex in the fourth quarter valued at approximately $45,000. 95.62% of the stock is currently owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.